MedTrace Logo

A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension

NCT07373613 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2026-01-28

No results posted yet for this study

Summary

The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

BR1400-1

One tablet administered alone

DRUG

BR1400-2

One tablet administered alone

DRUG

BR1400-3

One tablet administered alone

DRUG

BR1400-4

One tablet administered alone

DRUG

BR1400-5

One tablet administered alone

DRUG

BR1400-A

One tablet administered alone

DRUG

BR1400-B

One tablet administered alone

DRUG

BR1400-C

One tablet administered alone

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2027-02-01
Completion
2027-02-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07373613 on ClinicalTrials.gov